Vargatef nintedanib: Preliminary Phase I/II data

Preliminary data from 28 patients with advanced HCC in the dose-escalation Phase I portion of an open-label, European Phase I/II trial showed that the MTD of nintedanib was 200 mg given twice daily. T...